



(Please scan the QR code to view the Prospectus)



GPT HEALTHCARE LIMITED

Our Company was originally incorporated as “Jibansatya Printing House Private Limited”, a private limited company under the Companies Act, 1956 on August 17, 1989 at Kolkata, West Bengal. The name of our Company was subsequently changed to “GPT Healthcare Private Limited” so that the name of the Company is in consonance with the main objects of the Memorandum of Association in relation to the proposed business activities to be carried out by the Company. A fresh certificate of incorporation was issued by the Registrar of Companies, West Bengal at Kolkata (“RoC”) on March 31, 2005. Thereafter pursuant to a special resolution passed by our Shareholders on September 3, 2021, our Company was converted to a public limited company and our name was changed to “GPT Healthcare Limited”. A fresh certificate of incorporation consequent to change of name was issued by the RoC on September 15, 2021. For further details in relation to change in name and Registered and Corporate Office of our Company, see “History and Certain Corporate Matters” on page 232 of the prospectus dated February 26, 2024 filed with the RoC (“Prospectus”).

Registered and Corporate Office: GPT Centre, JC-25, Sector III, Salt Lake, Kolkata – 700106, West Bengal; Tel: + (91) 33 4050 7000; Contact Person: Ankur Sharma, Company Secretary and Compliance Officer; Tel: + (91) 33 4050 7000
E-mail: ghl.cosec@gptgroup.co.in; Website: www.ilshospitals.com; Corporate Identity Number: U70101WB1989PLC047402

THE COMMENCEMENT OF TRADING OF THE EQUITY SHARES OF OUR COMPANY ON THE STOCK EXCHANGES SHALL BE WITH EFFECT FROM THURSDAY, FEBRUARY 29, 2024. OUR COMPANY WILL BE LISTED ON T+3 DAY (T BEING THE ISSUE CLOSING DATE) IN TERMS OF THE TIMELINES PRESCRIBED UNDER THE SEBI CIRCULAR NO. SEBI/HO/CFD/TPD1/CIR/P/2023/140 DATED AUGUST 09, 2023.

OUR PROMOTERS: GPT SONS PRIVATE LIMITED, DWARIKA PRASAD TANTIA, DR. OM TANTIA AND SHREE GOPAL TANTIA

Our Company has filed the prospectus dated February 26, 2024 (“Prospectus”) with the RoC, and the Equity Shares are proposed to be listed on the Stock Exchanges and trading will commence from Thursday, February 29, 2024.

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFERING OF 28,233,323 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH (“EQUITY SHARES”) GPT HEALTHCARE LIMITED (OUR “COMPANY” OR THE “ISSUER”) FOR CASH AT A PRICE OF ₹ 186 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹176 PER EQUITY SHARE) (“OFFER PRICE”) AGGREGATING UP TO ₹ 5,251.40MILLION (THE “OFFER”) COMPRISING A FRESH ISSUE OF 2,150,537 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AGGREGATING TO ₹ 400.00 MILLION BY OUR COMPANY (THE “FRESH ISSUE”) AND AN OFFER FOR SALE OF 26,082,786 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AGGREGATING TO ₹ 4,851.40 MILLION BY BANYANTREE GROWTH CAPITAL II, LLC (THE “INVESTOR SELLING SHAREHOLDER”) (THE “OFFER FOR SALE”). THE OFFER WOULD CONSTITUTE 34.41 % OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

ANCHOR INVESTOR OFFER PRICE: ₹186 PER EQUITY SHARE OF FACE VALUE OF ₹10 EACH
OFFER PRICE: ₹186 PER EQUITY SHARE OF FACE VALUE OF ₹10 EACH
THE OFFER PRICE IS 18.6 TIMES OF THE FACE VALUE

RISKS TO INVESTORS:

- Regional Concentration Risk:** We derive approximately 70% of our revenue from operations from our hospitals situated in West Bengal as these serve a significant percentage of our patients. Further, all our hospitals are located in the eastern region of India. The revenue from operations of our three hospitals in West Bengal for six months ended September 30, 2023, six months ended September 30, 2022, Fiscal 2023, Fiscal 2022 and Fiscal 2021 was ₹1,432.41 million, ₹1,203.30 million, ₹2,554.10 million, ₹2,285.02 million and ₹1,643.19 million thus, resulting into a revenue contribution of 70.16%, 69.97%, 70.74%, 67.72% and 67.69%, respectively, of the revenue from operations of the Company. Any impact on the revenue from these hospitals or any change in the economic or political conditions of West Bengal could materially affect our business, financial condition, results of operations and cash flows.
- Risk in relation to a member of Promoter Group being a wilful defaulter:**
 - The name of Ishwari Prasad Tantia, one of the members of our Promoter Group was published in the list of Wilful Defaulters by certain financial institutions, due to default in repayment of a loan amounting to approximately ₹ 747 crore, obtained by Tantia Constructions Limited, wherein Ishwari Prasad Tantia is a Promoter.
 - Additionally, NSDL has frozen his demat account due to non-compliance with certain provisions of the Listing Regulations by Tantia Constructions Limited, wherein he is a promoter.
Any adverse order, direction, notice or penalty by any bank or the RBI, SEBI or any other regulatory authority in the future against any member of the Promoter Group or any entity with which any of our member of the Promoter Group is associated, could have an adverse effect on our reputation, consequently, affecting our business operations.
- Competition Risk:** We face competition from other healthcare service providers like hospitals, clinics, diagnostic chains, and dispensaries of varying sizes and specialties. Our competitors also include healthcare facilities owned or managed by government agencies and trusts, which may be able to obtain financing or make expenditure on more favourable terms than private healthcare facilities such as us. If we are unable to compete effectively, our business, results of operations and cash flows may be materially and adversely affected.
- Lower Bed Occupancy Rate:** The Bed Occupancy Rate of our Company is lower than some of our listed peers. If we are unable to maintain bed occupancy rates at sufficient levels, we may not be able to generate adequate returns on our capital expenditure, which could materially and adversely affect our operating efficiencies and our profitability.

Business Risks:

- We are dependent on our healthcare professionals, including our doctors that we engage on a consultancy basis. Loss of or our ability to attract or retain such persons could adversely affect our business, financial condition, results of operations and cash flows.

The attrition rate of our employees for the Fiscal Years 2023, 2022, 2021 and for the six months ended September 30, 2023 and September 30, 2022 is given in the table below:

Particulars	For the six months ended September 30, 2023	For the six months ended September 30, 2022	Fiscal Year 2023	Fiscal Year 2022	Fiscal Year 2021
Attrition (%)*	8.52%	8.87%	18.08%	24.73%	33.19%
Attrition (in number)	159	158	324	416	537

*Attrition is calculated as the number of exits divided by the average count of employees during the year / period.

- We are dependent on availability of nurses to provide quality healthcare services. A decline in the number of trained and available nurses may lead to a decline in our ability to provide required patient care and consequently adversely affect our operations and performance.

The following table sets forth the attrition rate for our doctors and nurses for the periods indicated below:

	Fiscal Year 2023	Fiscal Year 2022	Fiscal Year 2021
Doctors	11.83%	6.85%	16.39%
Nurses	22.45%	32.17%	44.22%

*Attrition is calculated as the number of exits divided by the average count of employees during the year / period.

- Dependency on Specialty Departments:** We are significantly dependent on certain specialties which accounted for 90.44%, 90.12%, 89.97%, 86.84% and 82.79% of our revenue from operations for the six months ended on September 30, 2023, six months ended on September 30, 2022, Fiscal Year 2023, Fiscal Year 2022 and Fiscal Year 2021, respectively. Any impact on our revenue from such specialties could have a material adverse effect on our business, financial condition, results of operations and cash flows.
- Payment Risk:** Our patients pay for our inpatient and outpatient services through a mix of cash on-site and credit arrangements, including through third-party payers such as private and public insurers. If we do not receive payments on time from our patients, our financial condition, cash flows and results of operations may be materially and adversely affected.

- Litigation risk:** We, our Promoters and Directors are involved in certain legal proceedings, any adverse developments related to which could affect our operations. We could suffer significant litigation expenses in defending these claims and could be subject to significant damage, compensation, or other remedies, which could adversely affect our reputation, business, results from operations, financial conditions and cash flows.
- Brand Risk:** Our business is highly dependent on the strength of our brand and reputation. Failure to maintain and enhance our brand and reputation, and any negative publicity and allegations in the media against us, may materially and adversely affect the level of market recognition, and trust in, our services, which could result in a material adverse impact on our business, financial condition, results of operations and prospects.
- Regulatory Risk:** Our industry is highly regulated and requires us to obtain, renew and maintain statutory and regulatory permits, accreditations, licenses and comply with applicable safety, health, environmental, labour and other governmental regulations. Any regulatory changes or violations of such rules and regulations may adversely affect our business, financial condition and results of operations.
- The Offer Price of our Equity Shares, our market capitalization to revenue from operations for FY 2023 and our price-to-earnings (P/E) ratio at Offer Price may not be indicative of the market price of our Equity Shares after the Offer.

Particulars	Ratio vis-à-vis Floor Price of ₹ 177	Ratio vis-à-vis Cap Price of ₹ 186
	(In multiples, unless otherwise specified)	
Market capitalization to Revenue from Operations	4.03	4.23
Price-to-earnings ratio	36.27	38.11
Average Price-to-earnings ratio of the Industry peers	56.36	

Notes:

- Market capitalization has been computed as the product of number of shares outstanding as on the date of RHP with the Floor Price or Cap Price, as applicable.
- Revenue from Operations are for the Financial Year ended March 31, 2023.
- P/E Ratio has been computed based on the Floor Price or Cap Price, as applicable, divided by the Diluted EPS for the Financial Year ended 2023.
- P/E ratio for the Industry peers are computed based on closing market price as on January 29, 2024 at NSE or BSE, as the case may be, divided by Diluted EPS (on consolidated basis) based on the annual report of the company for the Financial Year 2023.
- The average cost of acquisition of Equity Shares held by the Promoters ranges from ₹8.67 to ₹18.00 per Equity Share and that of the Investor Selling Shareholder is ₹15.34 and Offer Price at higher end of the Price Band is ₹186 per Equity Share.
- The Price/Earnings Ratio based on diluted EPS for Financial Year 2023 for the Company at the higher end of the Price Band is as high as 38.11 times and at the lower end of the Price Band is 36.27 times as compared to the average industry peer group PE ratio of 56.36 times.
- Weighted Average Return on Net Worth for past three Fiscals i.e. 2023, 2022 and 2021 is 23.38%.
- Details of weighted average cost of acquisition of all Equity Shares transacted in last one year, eighteen months and three years immediately preceding the date of the RHP is set forth below:

Period	Weighted average cost of acquisition (in ₹)	Cap Price is ‘x’ times the weighted average cost of acquisition	Range of acquisition (Lowest Price-Highest Price) (in ₹)
Last one year	Nil	Not Applicable	Not Applicable
Last eighteen months	Nil	Not Applicable	Not Applicable
Last three years	6.46	28.79	Nil to 54.00

As certified by M/s Agarwal Lodha & Co., Chartered Accountants, pursuant to their certificate dated February 16, 2024.

- Weighted average cost of acquisition based on Past Allotment(s)/ Secondary Transaction(s), floor price and cap price

Types of transactions	Weighted average cost of acquisition (₹ per Equity Share)	Floor price (i.e., ₹ 177)	Cap price (i.e., ₹ 186)
Weighted average cost of acquisition of primary transaction in last three years	6.46	27.40 times	28.79 times
Weighted average cost of acquisition of last five secondary transactions in last three years*	18.00	9.83 times	10.33 times

As certified by M/s Agarwal Lodha & Co., Chartered Accountants, pursuant to their certificate dated February 16, 2024.

* Secondary transactions where Promoters, Promoter Group entities, Investor Selling Shareholder or shareholders having the right to nominate the directors on the Board of our Company are a party to the transaction.

- The BRLM associated with the Offer have handled 50 public issues in the past three years, out of which 11 issues closed below the offer price on listing date.

Name of BRLM	Total Issues	Issues Closed Below IPO Price on Listing Date
JM Financial Limited	50	11

BID/OFFER PERIOD

ANCHOR INVESTOR BIDDING DATE: OPENED AND CLOSED ON WEDNESDAY, FEBRUARY 21, 2024
BID/OFFER OPENED ON THURSDAY, FEBRUARY 22, 2024 | BID/OFFER CLOSED ON MONDAY, FEBRUARY 26, 2024

...continued from previous page.

This was an Offer in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”), read with Regulation 31 of the SEBI ICDR Regulations. The Offer was being made through the Book Building Process in terms of Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Offer was available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs and such portion, the “QIB Portion”). Our Company, in consultation with the BRLM, allocated up to 60% of the QIB Portion to Anchor Investors on a discretionary basis (“Anchor Investor Portion”), out of which one-third was reserved for domestic Mutual Funds only, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation was made to Anchor Investors (“Anchor Investor Allocation Price”), in accordance with the SEBI ICDR Regulations. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares were added to the QIB Portion (excluding the Anchor Investor Portion) (“Net QIB Portion”). Further, 5% of the Net QIB Portion was available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion was available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received from them at or above the Offer Price. However, if the aggregate demand from Mutual Funds was less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion were added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Offer was available for allocation to Non-Institutional Bidders of which one-third portion was available for allocation to Non-Institutional Bidders with a Bid size of more than ₹ 0.20 million and up to ₹ 1.00 million and two-third portion was available for allocation to Non-Institutional Bidders with a Bid size of more than ₹ 1.00 million, provided that unsubscribed portion in either of such sub-categories was allocated to applicants in the other sub-category of Non-Institutional Bidders in accordance with the SEBI ICDR Regulations and not less than 35% of the Offer was available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price all potential Bidders (except Anchor Investors) were mandatorily required to utilize the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective ASBA accounts and UPI ID in case of UPI Bidders using the UPI Mechanism, as applicable, pursuant to which their corresponding Bid Amount were blocked by the Self Certified Syndicate Banks (“SCSBs”) or by the Sponsor Banks under the UPI Mechanism, as the case may be, to the extent of the respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA Process. For further details, see “Offer Procedure” on page 461 of the Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, February 21, 2024. The Company received 15 Anchor Investor Application Forms from 11 Anchor Investors (including 03 domestic mutual funds through 07 Mutual Fund schemes) for 9,545,520 Equity Shares. The Anchor Investor Offer Price was finalized at ₹186 per Equity Share. A total of 8,469,996 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 1,575,419,256.00.

The Offer received 244,895 applications for 178,126,560 Equity Shares resulting in 6.31 times subscription. The details of the applications received in the Offer from Retail Individual Bidders, Non-Institutional Bidders and QIBs are as under (before rejections):

Sl. No.	CATEGORY	NO. OF APPLICATIONS APPLIED	NO. OF EQUITY SHARES	EQUITY SHARES RESERVED AS PER PROSPECTUS	NO. OF TIMES SUBSCRIBED	AMOUNT (₹)
A	Retail Individual Bidders	227,457	24,146,240	9,881,664	2.44	4,491,534,400.00
B	Non-Institutional Bidders – More than ₹ 2 lakhs and upto ₹10 lakhs	11,223	13,037,680	1,411,667	9.24	2,424,951,680.00
C	Non-Institutional Bidders – More than ₹10 lakhs	6,164	34,096,160	2,823,332	12.08	6,341,885,760.00
D	Qualified Institutional Bidders (excluding Anchors Investors)	36	97,300,960	5,646,664	17.23	18,097,978,560.00
E	Anchor Investors	15	9,545,520	8,469,996	1.13	1,775,466,720.00
	Total	244,895	178,126,560	28,233,323	6.31	33,131,817,120.00

Final Demand

A summary of the final demand as per NSE and BSE as on the Bid/Offer Closing Date at different Bid prices is as under:

Sr. No	Bid Price (₹)	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1	177	303,200	0.16	303,200	0.16
2	178	40,560	0.02	343,760	0.18
3	179	18,400	0.01	362,160	0.19
4	180	170,320	0.09	532,480	0.28
5	181	25,440	0.01	557,920	0.30
6	182	39,840	0.02	597,760	0.32
7	183	18,400	0.01	616,160	0.33
8	184	37,600	0.02	653,760	0.35
9	185	66,640	0.04	720,400	0.38
10	186	150,846,480	80.36	151,566,880	80.74
11	Cut-Off	36,145,680	19.26	187,712,560	100.00
	TOTAL	187,712,560	100.00		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE on February 27, 2024.

A. Allotment to Retail Individual Bidders (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Retail Individual Bidders, who have bid at cut-off or at the Offer Price of ₹186 per Equity, was finalized in consultation with BSE. This category has been subscribed to the extent of 2.35 times (after rejections). The total number of Equity Shares Allotted in Retail Portion is 9,881,664 Equity Shares to 123,520 successful Retail Individual Bidders. The category-wise details of the Basis of Allotment are as under:

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	80	194,545	88.89	15,563,600	67.08	80	57:101	8,783,440
2	160	12,921	5.90	2,067,360	8.91	80	57:101	583,360
3	240	3,814	1.74	915,360	3.95	80	57:101	172,160
4	320	1,604	0.73	513,280	2.21	80	57:101	72,400
5	400	1,548	0.71	619,200	2.67	80	57:101	69,920
6	480	679	0.31	325,920	1.40	80	57:101	30,640
7	560	681	0.31	381,360	1.64	80	57:101	30,720
8	640	324	0.15	207,360	0.89	80	57:101	14,640
9	720	192	0.09	138,240	0.60	80	57:101	8,640
10	800	713	0.33	570,400	2.46	80	57:101	32,160
11	880	81	0.04	71,280	0.31	80	46:81	3,680
12	960	132	0.06	126,720	0.55	80	57:101	6,000
13	1040	1,636	0.75	1,701,440	7.33	80	57:101	73,840
	13727 Allottees from Serial no 2 to 13 Additional 1(one) share					1	64:13727	64
	TOTAL	218,870	100.00	23,201,520	100.00			9,881,664

B. Allotment to Non-Institutional Bidders (more than ₹0.20 million and upto ₹1.00 million) (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹ 0.20 million and upto ₹1 million), who have bid at the Offer Price of ₹ 186 per Equity Share or above, was finalized in consultation with BSE. This category has been subscribed to the extent of 9.08 times (after rejections). The total number of Equity Shares allotted in this category is 1,411,667 Equity Shares to 1,260 successful Non-Institutional investors. The category-wise details of the Basis of Allotment are as under: (Sample)

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	1,120	10497	95.16	11,756,640	91.74	1,120	4:35	1,342,880
2	1,200	154	1.40	184,800	1.44	1,127	18:154	20,286
3	1,280	32	0.29	40,960	0.32	1,127	4:32	4,508
4	1,360	41	0.37	55,760	0.44	1,127	5:41	5,635
5	1,440	12	0.11	17,280	0.13	1,127	1:12	1,127
6	1,600	45	0.41	72,000	0.56	1,127	5:45	5,635
7	1,680	26	0.24	43,680	0.34	1,127	3:26	3,381
8	2,000	18	0.16	36,000	0.28	1,127	2:18	2,254
9	2,080	6	0.05	12,480	0.10	1,127	1:6	1,127
10	2,160	7	0.06	15,120	0.12	1,127	1:7	1,127
11	2,240	12	0.11	26,880	0.21	1,127	1:12	1,127
12	2,320	5	0.05	11,600	0.09	1,127	1:5	1,127
13	2,400	11	0.10	26,400	0.21	1,127	1:11	1,127
14	2,640	76	0.69	200,640	1.57	1,127	9:76	10,143
15	2,720	8	0.07	21,760	0.17	1,127	1:8	1,127
16	2,800	5	0.05	14,000	0.11	1,127	1:5	1,127
17	3,040	11	0.10	33,440	0.26	1,127	1:11	1,127
18	3,200	6	0.05	19,200	0.15	1,127	1:6	1,127
19	4,480	5	0.05	22,400	0.17	1,127	1:5	1,127
20	5,360	14	0.13	75,040	0.59	1,127	2:14	2,254
501	1,520	2	0.02	3,040	0.02	1,127	0:2	0
502	1,760	3	0.03	5,280	0.04	1,127	0:3	0
503	1,840	4	0.04	7,360	0.06	1,127	0:4	0
504	1,920	3	0.03	5,760	0.04	1,127	0:3	0
505	2,480	1	0.01	2,480	0.02	1,127	0:1	0
506	2,560	4	0.04	10,240	0.08	1,127	0:4	0
507	2,880	1	0.01	2,880	0.02	1,127	0:1	0
508	2,960	2	0.02	5,920	0.05	1,127	0:2	0
509	3,280	1	0.01	3,280	0.03	1,127	0:1	0
510	3,360	3	0.03	10,080	0.08	1,127	0:3	0
511	3,520	1	0.01	3,520	0.03	1,127	0:1	0
512	3,760	1	0.01	3,760	0.03	1,127	0:1	0
513	3,840	1	0.01	3,840	0.03	1,127	0:1	0
514	3,920	1	0.01	3,920	0.03	1,127	0:1	0
515	4,320	1	0.01	4,320	0.03	1,127	0:1	0
516	4,400	2	0.02	8,800	0.07	1,127	0:2	0

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
517	4,560	1	0.01	4,560	0.04	1,127	0:1	0
518	4,800	4	0.04	19,200	0.15	1,127	0:4	0
519	4,960	1	0.01	4,960	0.04	1,127	0:1	0
520	5,040	1	0.01	5,040	0.04	1,127	0:1	0
521	5,200	1	0.01	5,200	0.04	1,127	0:1	0
522	5,280	1	0.01	5,280	0.04	1,127	0:1	0
523	All applicants from Serial no 501 to 522 for 1 (one) lot of 1127 shares					1,127	2:40	2,254
524	61 Allottees from Serial no 2 to 523 Additional 1(one) share					1	40:61	40
	TOTAL	11,031	100	12,814,800	100			1,411,667

C. Allotment to Non-Institutional Bidders (more than ₹1.00 million) (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹1 million), who have bid at the Offer Price of ₹186 per Equity Share or above, was finalized in consultation with BSE. This category has been subscribed to the extent of 12.01 times. The total number of Equity Shares allotted in this category is 2,823,332 Equity Shares to 2,520 successful Non-Institutional investors. The category-wise details of the Basis of Allotment are as under: (Sample)

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares Applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares Allotted
1	5,440	5937	96.87	32,297,280	95.26	1,120	51:124	2,735,040
2	5,520	54	0.88	298,080	0.88	1,120	22:54	24,640
3	5,600	30	0.49	168,000	0.50	1,120	12:30	13,440
4	5,680	6	0.10	34,080	0.10	1,120	2:6	2,240
5	5,760	8	0.13	46,080	0.14	1,120	3:8	3,360
6	5,840	6	0.10	35,040	0.10	1,120	2:6	2,240
7	6,000	11	0.18	66,000	0.19	1,120	5:11	5,600
8	6,080	9	0.15	54,720	0.16	1,120	4:9	4,480
9	6,160	2	0.03	12,320	0.04	1,120	1:2	1,120
10	6,400	4	0.07	25,600	0.08	1,120	2:4	2,240
11	6,560	7	0.11	45,920	0.14	1,120	3:7	3,360
12	7,360	2	0.03	14,720	0.04	1,120	1:2	1,120
13	7,440	2	0.03	14,880	0.04	1,120	1:2	1,120
14	7,680	2	0.03	15,360	0.05	1,120	1:2	1,120
15	8,000	6	0.10	48,000	0.14	1,120	2:6	2,240
16	8,240	7	0.11	57,680	0.17	1,120	3:7	3,360
17	9,520	2	0.03	19,040	0.06	1,120	1:2	1,120
18	10,000	2	0.03	20,000	0.06	1,120	1:2	1,120
19	10,800	3	0.05	32,400	0.10	1,120	1:3	1,120
20	11,120	2	0.03	22,240	0.07	1,120	1:2	1,120
21	16,000	4	0.07	64,000	0.19	1,120	2:4	2,240
1001	5,920	1	0.02	5,920	0.02	1,120	0:1	0
1002	6,240	1	0.02	6,240	0.02	1,120	0:1	0
1003	6,320	1	0.02	6,320	0.02	1,120	0:1	0
1004	8,080	1	0.02	8,080	0.02	1,120	0:1	0
1005	8,560	1	0.02	8,560	0.03	1,120	0:1	0
1006	9,600	1	0.02	9,600	0.03	1,120	0:1	0
1007	10,720	1	0.02	10,720	0.03	1,120	0:1	0
1008	11,200	1	0.02	11,200	0.03	1,120	0:1	0
1009	11,280	1	0.02	11,280	0.03	1,120	0:1	0
1010	11,360	1	0.02	11,360	0.03	1,120	0:1	0
1011	11,680	1	0.02	11,680	0.03	1,120	0:1	0
1012	12,000	1	0.02	12,000	0.04	1,120	0:1	0
1013	14,000	1	0.02	14,000	0.04	1,120	0:1	0
1014	14,160	1	0.02	14,160	0.04	1,120	0:1	0
1015	14,800	1	0.02	14,800	0.04	1,120	0:1	0
1016	17,600	1	0.02	17,600	0.05	1,120	0:1	0
1017	20,000	1	0.02	20,000	0.06	1,120	0:1	0
1018	22,400	1	0.02	22,400	0.07	1,120	0:1	0
1019	32,000	1	0.02	32,000	0.09	1,120	0:1	0
1020	48,000	1	0.02	48,000	0.14	1,120	0:1	0
1021	50,400	1	0.02	50,400	0.15	1,120	0:1	0
1022	64,000	1	0.02	64,000	0.19	1,120	0:1	0
1023	104,000	1	0.02	104,000	0.31	1,120	0:1	0
1024	All applicants from Serial no 1001 to 1023 for 1 (one) lot of 1120 shares					1,120	8:23	8,960
1025	2520 Allottees from Serial no 1 to 1024 Additional 1(one) share					1	27:73	932
	TOTAL	6,129	100	33,905,760	100			2,823,332